

November 29, 2018

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that subject to applicable laws, Drug Discovery and Development Solutions Limited, Singapore ('DDDSL'), a wholly-owned subsidiary company, has entered into Stock Purchase Agreement on November 29, 2018 for acquiring 534,194 shares of Common Stock of Inipharm Inc., USA.

Relevant details are given in **Annexure-A** to this letter.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

Details of Acquisition of Equity Shares by Drug Discovery and Development Solutions Limited, Singapore (a wholly-owned subsidiary of the Company)

| Sr. No. | Particulars | Details |
|---------|---|--|
| 1. | Name of the target entity, details in brief such as size, turnover etc. | Inipharm Inc., USA <u>FY 2017-18:</u> • <u>Turnover</u> : NIL • <u>EBITDA</u> : NIL |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length” | No |
| 3. | Industry to which the entity being acquired belongs | Biotechnology |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | Early stage Drug Discovery research Investment |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| 6. | Indicative time period for completion of the acquisition | Three months |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same | Cash consideration |
| 8. | Cost of acquisition or the price at which the shares are acquired | USD 534.20 (USD Five Hundred Thirty Four and Twenty cents only) |



JUBILANT LIFESCIENCES

| Sr. No. | Particulars | Details |
|---------|--|---|
| 9. | Percentage of shareholding/ control acquired and/ or number of shares acquired; | 534,194 shares of Common Stock of USD 0.001 each aggregating to USD 534.20 (USD Five Hundred Thirty Four and Twenty cents only) i.e. 10% shares of Common Stock. |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | <p>The relevant details of Inipharm Inc. are given below:</p> <ul style="list-style-type: none">• <u>Products/line of business:</u> Drug Discovery and Development• <u>Date of incorporation:</u> July 23, 2018• <u>Turnover of last three years:</u> <u>Newly incorporated</u> 2015-16: NIL 2016-17: NIL 2017-18: NIL• <u>Country in which Inipharm Inc. has presence:</u> USA• <u>Any other significant information:</u> NIL |

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624